Branded drugs and over-stickering: when is 8.62% a substantial part? – Technology Law Update

‘A brand-owner generally wants to use the same brand across several countries, but there are industries where national branding is common. Pharmaceuticals is one. In a free trade bloc like the EU this leads to a tension between the free movement of goods and protection of IP rights. The interplay of the EU rules in this area has come under the spotlight in SEP v Doncaster.’

Full story

Technology Law Update, 6th March 2015